236 results Stibbe advises Tornier Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion. Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business. Stibbe advises Pilkington Successfully defended Pilkington in proceedings against an ACM decision to impose a fine for alleged participation in a cartel in the double-glass sector. Stibbe advises Aalberts Industries Successfully defended Aalberts Industries in a Commission appeal against a General Court judgment that had struck down a EUR 100+ million fine imposed on Aalberts. Stibbe advises Mars Representing Mars in legal proceedings before the District Court against Nestlé on allegations of abuse of dominance in the chocolate market. Stibbe advises AkzoNobel Assisting AkzoNobel in proceedings before the EU General Court concerning the European Commission's attempt to re-publish an extended non-confidential version of the hydrogen peroxide cartel decision (that includes leniency information). Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets. Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here. Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products. Stibbe advises suspects in the so-called Real Estate Fraud case Stibbe advises confidential client Stibbe advises Plantion Representing Plantion/FloraHolland in litigation before the District Court. Stibbe advises Grain Millers Representing Grain Millers in an appeal against a fine in the flour sector that resulted in a lower fine. Stibbe advises Universal Corporation Representing Universal Corporation in proceedings against the European Commission before the EU General Court with regard to the taking back of the grant of leniency and parent/subsidiary liability. Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding. Stibbe advises ROC Mondriaan, ROC Amsterdam, Albeda College and Zadkine Stibbe advises KLM Royal Dutch Airlines Advising KLM on several environmental and planning aspects. Pagination Previous page Page 11 Current page 12 Page 13 Page 14 Next page
Stibbe advises Tornier Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion.
Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.
Stibbe advises Pilkington Successfully defended Pilkington in proceedings against an ACM decision to impose a fine for alleged participation in a cartel in the double-glass sector.
Stibbe advises Aalberts Industries Successfully defended Aalberts Industries in a Commission appeal against a General Court judgment that had struck down a EUR 100+ million fine imposed on Aalberts.
Stibbe advises Mars Representing Mars in legal proceedings before the District Court against Nestlé on allegations of abuse of dominance in the chocolate market.
Stibbe advises AkzoNobel Assisting AkzoNobel in proceedings before the EU General Court concerning the European Commission's attempt to re-publish an extended non-confidential version of the hydrogen peroxide cartel decision (that includes leniency information).
Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets.
Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here.
Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b
Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.
Stibbe advises Grain Millers Representing Grain Millers in an appeal against a fine in the flour sector that resulted in a lower fine.
Stibbe advises Universal Corporation Representing Universal Corporation in proceedings against the European Commission before the EU General Court with regard to the taking back of the grant of leniency and parent/subsidiary liability.
Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.